Editor’s Note: “Every drug can be made and every disease can be treated”. Since 2000, from a single laboratory to a global network spanning Asia, Europe, and North America; from early chemical synthesis services to an integrated platform that connects Research (R), Development (D), and Manufacturing (M); from its very first customer to thousands of partners across more than 30 countries, WuXi AppTec has never stopped moving forward to realize its enduring vision. 

In tribute to the journey, we look back through the eyes of our “dream-makers”: revisiting the stories of partnership that empowered global innovation, and the unique spirit that continues to guide us toward the next chapter.

On weekends, when the emails slow and the lights dim in the office, you might find Dirk Tormans doing something unhurried: walking. Long stretches of trails and quiet city paths give him time to reflect, to unwind, to think several steps ahead. And when he is not walking, he immerses himself in strategy games. He smiles when he explains this hobby, and it makes perfect sense. Strategy games require planning, discipline, anticipation, and the willingness to learn from experience. In many ways, they echo the mindset that guides his work.

Over the past three decades, that mindset has shaped a quality system that supports innovators around the world as they develop new medicines, advance regulatory submissions, and move therapies from discovery to patients. It is a system defined not only by compliance, but by consistency, transparency, trust, and shared purpose.

A System Built to Be Inspection-Ready, Every Day

When a regulatory authority or a client walks into a WuXi AppTec site, the system they encounter is not assembled for a single audit; it is designed for daily execution. This principle has shaped the company’s approach to quality under the leadership of Dirk, Head of QA, who describes his role as less about directing and more about facilitating a system in which quality is part of how people work every day. He often notes that quality cannot be something performed only when someone is watching; it must be embedded in routine practice, in how records are kept, how deviations are handled, and how teams understand procedures, and the reasons behind them. 

This philosophy was evident during a recent unannounced FDA inspection, a common practice to ensure GMP quality, at one of WuXi AppTec’s manufacturing sites. Investigators arrived without prior notification and began their review. The teams did not need to adjust or prepare; they continued operating under their established systems. The inspection concluded with no observations. For Dirk, the significance was not the result itself, but what it confirmed: a system in which readiness is the everyday state, not a special event.

The foundation for this readiness is a structured quality framework that spans the full arc of pharmaceutical manufacturing: from raw-material qualification and supplier oversight, through production execution and equipment calibration, to analytical verification, packaging, storage, and shipment. Dirk emphasizes that this framework is strengthened by people, not just procedures. He frequently points to the dedication of site teams, describing quality as “a total company responsibility,” upheld through collaboration and shared accountability. 

In more than two decades of global operations, this framework has been examined in hundreds of regulatory inspections across agencies worldwide. During this period, WuXi AppTec reports no critical regulatory findings, no enforcement actions, and no product recalls. In a landscape where a single recall can disrupt patient access to essential therapies, this sustained history reflects not only technical rigor, but the shared commitment of thousands of people to protect patient safety.

One Global Quality System, Consistency Across Continents

As WuXi AppTec’s platform has expanded across regions and time zones, Dirk has focused on ensuring that quality feels familiar wherever work is done. This effort, years in the making, began with global growth in mind and centered on a practical aim: people at different sites should follow comparable ways of working and understand why those practices matter. This approach led to the One Global Quality System, a unified framework that aligns expectations across locations. 

A key step in making this possible was transitioning from paper-based processes to global computerized systems. This shift did more than digitize records; it allowed decisions and quality documentation to be interpreted consistently across the network. It helped sites speak the same “quality language,” reduced ambiguity, and supported oversight without duplication. 

Within this framework are global quality procedures: standardized GMP and best-practice requirements co-developed by subject-matter experts across the network. Once approved, these procedures are implemented through standardized training, ensuring that teams understand not only what to do, but how their work will be evaluated across the organization. 

The integration of the Couvet, Switzerland, manufacturing site demonstrates how the One Global Quality System is implemented. Rather than building a new local system, Couvet is connected to the established global framework; adopting the same global quality procedures, computerized systems, and standardized training used across the network. QA leaders from other sites spent time in Couvet to understand routines, explain expectations, and map local processes to the global framework. Subsequent inspections by Swissmedic, the FDA, and Brazil’s ANVISA proceeded without interrupting production, indicating that the site had fully aligned to the global system as intended.

The same approach guides newer sites in Middletown, Delaware, and Singapore. Dirk notes that leaders are being embedded early, and quality systems are established before operations begin. In Dirk’s words, the work is about “building bridges” among sites so that knowledge moves with people and questions are resolved consistently and transparently. Consistency, in his view, is not identical facilities; it is a shared standard, supported by common systems, procedures, and training, that allows work to be understood and improved across the network. 

Dirk confirms that clients repeatedly validate the impact of this approach. “Very often I get feedback that they experience a consistent quality of service across the sites,” he says. In practice, that consistency saves time and costs: for example, a qualification audit at an API site often lets them limit audit time at a downstream drug-product site because the procedures, computerized systems, and training are the same.

Quality Culture: the Human Foundation that Creates Client Experience

Yet the strongest systems in the world cannot function without the right culture. For Dirk, culture is where quality truly lives. He believes that WuXi AppTec’s quality culture aligns with its simple, but meaningful principle: “Doing the right thing; Doing it right.” Doing the right thing reflects intent: acting in the interest of patient safety and scientific integrity. Doing it right speaks to discipline: carrying out the work with rigor and clarity, so that decisions stand up to scrutiny.

This mindset shapes daily actions. Quality is not the responsibility of one department; it is the responsibility of everyone. This shared ownership means deviations are not hidden or minimized but openly examined. Mistakes are treated not as failures to be punished, but as opportunities to understand, learn, and prevent recurrence. Teams support each other across functions and sites when challenges arise, reflecting a belief that success and improvement belong to the whole organization.

Clients also experience this culture during their own audits. WuXi AppTec hosts hundreds of client audits each year, and the tone is consistent: transparent, welcoming, collaborative. Instead of treating audits as disruptions, teams treat them as opportunities to strengthen the system, demonstrate confidence in practice, and learn from external perspectives. 

Clients frequently describe the experience as reassuring: not because everything is perfect, but because the organization approaches both strengths and challenges with maturity and openness. As Dirk explains, clients consistently share the same takeaway after an audit: The quality system is very mature, and they feel very confident in how it is executed. They may offer recommendations, and these are always welcomed. What clients see in the closeout discussions is a commitment to take every observation seriously, evaluate it carefully, and use it to drive continuous improvement. 

For many emerging biotechnology companies, WuXi AppTec’s quality infrastructure becomes more than a service. It serves as a cornerstone of regulatory credibility, an enabler of INDs and marketing submissions, and ultimately, a safeguard for the patients they hope to reach.

Looking Ahead, Preparing for the Next Era

The future of quality assurance is evolving. Advanced therapeutic modalities will demand deeper integration between analytical development and manufacturing control. Regulatory oversight is shifting toward real-time evaluation, continuous monitoring, and data-driven assessment of quality maturity. Predictive analytics, digital batch records, and eventually real-time release will reshape how manufacturing and quality teams interact.

Dirk is preparing for that future now: strengthening infrastructure, developing cross-site leadership, and ensuring that every new site is not just compliant, but capable of sustaining excellence from Day One.

When asked what WuXi AppTec’s vision — “Every drug can be made and every disease can be treated” — means to him, Dirk answers with quiet clarity:

“It means we work hard every day to make sure patients can receive high quality and new medicines they need.”

And then, when the workday ends, he walks again, steady, thoughtful, and deliberate. Because quality is not a destination. It is a journey. And Dirk is still walking it.